Related Experiment Video

Updated: Jul 1, 2025

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.1K

Treatment-related neuroendocrine prostate cancer with BRCA2 germline mutation treated with olaparib

Riko Ikeda1, Yoh Matsuoka1, Masaharu Inoue1

  • 1Department of Urology Saitama Cancer Center Saitama Japan.

IJU Case Reports
|March 5, 2024
PubMed
Abstract

Insights

Olaparib shows 1-year efficacy in a patient with treatment-related neuroendocrine prostate cancer and a BRCA2 mutation. This PARP inhibitor offers a potential treatment option for this rare cancer subtype.

Area of Science:

  • Oncology
  • Genetics
  • Prostate Cancer Research

Background:

  • Neuroendocrine prostate cancer (NEPC) is a rare and aggressive subtype.
  • Treatment-related NEPC can arise after androgen deprivation therapy for prostate adenocarcinoma.
  • The efficacy of targeted therapies in treatment-related NEPC remains largely uncharacterized.

Observation:

  • A 75-year-old male developed treatment-related NEPC after 10 years of androgen deprivation therapy.
  • Initial chemotherapy (etoposide and carboplatin) provided temporary response, followed by recurrence.
  • Genetic testing revealed a BRCA2 mutation.

Findings:

  • Olaparib, a PARP inhibitor, was administered after a repeat chemotherapy course.
  • The patient experienced sustained tumor regression for one year on olaparib.
  • No severe side effects were observed during olaparib treatment.

Implications:

  • Olaparib demonstrates potential as a treatment of choice for treatment-related NEPC in patients with BRCA mutations.
  • This case highlights the importance of genetic profiling in guiding therapy for advanced prostate cancer.
  • Further investigation into PARP inhibitors for NEPC is warranted.
Keywords:
BRCA2castration‐resistantneuroendocrine tumorpoly(ADP‐ribose) polymerase inhibitorsprostate cancer

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Evaluating In Vitro DNA Damage Using Comet Assay10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

37.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K